XRTX
XORTX Therapeutics Inc. Common Stock
Pharmaceutical Preparations
Best Pharmaceutical Stocks 2026 →
XORTX Therapeutics (XRTX) Stock: Buy, Sell, or Hold?
$0.85
+0.01 (+0.59%)
▲
5d:
-15.0%
30d:
-50.58%
90d:
-60.67%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (57%)
Quality Score
38/100
Position
OVERSOLD
30-Day Fair Range
$0.88 – $1.54
Position: OVERSOLD
Forward P/E & Valuation
0.8x
CHEAP
vs 1.6x historical avg
Wall Street Target
$14.04
+1551.3% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$0.83 / $1.15
Trend: Strong Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
⏸️ WAIT FOR STABILIZATION: XRTX is down 15.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Get Alerted When XRTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$2.47
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$1.53
44.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 1.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: XRTX is currently trading at $0.85, which is considered oversold relative to its 30-day fair value range of $0.88 to $1.54. From a valuation perspective, the stock is trading at a discount (Forward PE: 0.8) compared to its historical average (1.6). Remarkably, the market is currently pricing in an annual earnings decline of 22.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, XRTX is in a strong downtrend. The price is currently testing key support at $0.83. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: XRTX scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $14.04 (+1551.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, XRTX is in a strong downtrend. The price is currently testing key support at $0.83. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: XRTX scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $14.04 (+1551.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.88 -
$1.54
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
57.1%
Trading Range & Key Levels
30-Day Trading Range
$0.88 -
$1.54
Current vs Trading Range
OVERSOLD
Support Level
$0.83
Resistance Level
$1.15
Current Trend
Strong Downtrend
Technical data as of
Nov 10, 2026
Quantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (35/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 1551.3% below Wall St target ($14.04)
- WARNING: Composite score 38/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
0.77
Wall Street Target
$14.04
(+1551.3%)
Earnings Growth (YoY)
-97.2%
Valuation Discount vs History
-22.4% cheaper
PE vs Historical
0.8 vs 1.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-22.4%
(market-implied from PE analysis)
1-Year Target
$0.77
(-10%)
2-Year Target
$0.69
(-19%)
3-Year Target
$0.62
(-27%)
3-Yr Target (if PE normalizes)
(PE: 1→2)
$1.28
(+51%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 0.8 to 1.6
Stabilization Target:
$1.76
(+107.2%)
PE Expansion Potential:
+107.2%
Share XRTX Analysis
Share this live XRTX analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (XRTX)
Bullish
13 Retail Mentions
StockTwits Volume
13 msgs
24h retail stream
Last Tracked
Oct 12, 2026
Daily AI digest
AI Retail Discussion Summary:
StockTwits is currently flooded with bullish sentiment towards $XRTX, with traders expressing confidence in the stock's potential for significant gains and anticipating a breakout above current resistance levels.
Key Retail Themes:
Anticipation of a significant breakout
Confidence in the stock's potential for large gains
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 11, 2026 7:58 AM ET
Data refreshes hourly during market hours. Next update: 8:58 AM
Data refreshes hourly during market hours. Next update: 8:58 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XRTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
BUY
28 analysts |
$978 | 37 SELL |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$296 | 43 HOLD |
|
PRAX
Praxis Precision Medicin… |
STRONG BUY
21 analysts |
$650 | 36 SELL |
|
NAMS
NewAmsterdam Pharma Comp… |
STRONG BUY
16 analysts |
$50 | 49 HOLD |
|
CGEM
Cullinan Oncology LLC |
STRONG BUY
12 analysts |
$35 | 57 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive XRTX Research Pages
